140 related articles for article (PubMed ID: 11249073)
21. Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals.
Zucker KA; Adrian TE; Bilchik AJ; Modlin IM
Am J Physiol; 1989 Oct; 257(4 Pt 1):G511-6. PubMed ID: 2478030
[TBL] [Abstract][Full Text] [Related]
22. The trophic response of rat pancreas to sulfated cholecystokinin-8 is dose- and time-dependent and not affected by vagotomy or atropine.
Nylander AG; Chen D; Ding XQ; Norlén P; Håkanson R
Pharmacol Toxicol; 1997 Mar; 80(3):142-6. PubMed ID: 9101587
[TBL] [Abstract][Full Text] [Related]
23. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
Jia D; Yamamoto M; Otsuki M
World J Gastroenterol; 2015 Jul; 21(25):7742-53. PubMed ID: 26167074
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic regeneration after ethionine-induced acute pancreatitis in rats lacking pancreatic CCK-A receptor gene expression.
Sato T; Niikawa J; Usui I; Imamura T; Yoshida H; Tanaka S; Mitamura K
J Gastroenterol; 2003; 38(7):672-80. PubMed ID: 12898360
[TBL] [Abstract][Full Text] [Related]
25. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
Nakano S; Kihara Y; Otsuki M
Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
[TBL] [Abstract][Full Text] [Related]
26. Regulation of cholecystokinin release and transcription in a rat without gene expression of cholecystokinin-A receptor.
Miyasaka K; Masuda M; Funakoshi A
Digestion; 1997; 58(2):104-10. PubMed ID: 9144298
[TBL] [Abstract][Full Text] [Related]
27. Neurohormonal regulation of pancreatic exocrine function in rats without gene expression of the cholecystokinin-A receptor.
Miyasaka K; Masuda M; Kawanami T; Funakoshi A
Pancreas; 1996 Apr; 12(3):272-9. PubMed ID: 8830334
[TBL] [Abstract][Full Text] [Related]
28. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403.
Ohkoshi M; Okuda S
Anticancer Res; 2002; 22(2A):821-3. PubMed ID: 12014657
[TBL] [Abstract][Full Text] [Related]
29. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas.
Povoski SP; Zhou W; Longnecker DS; Bell RH
Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527
[TBL] [Abstract][Full Text] [Related]
30. Continuous infusion of cholecystokinin leads to down-regulation of the cholecystokinin-A receptor in the rat pancreas.
Ohlsson B; Borg K; Mulder H; Rehfeld JF; Axelson J; Sundler F
Scand J Gastroenterol; 2000 Jun; 35(6):612-8. PubMed ID: 10912661
[TBL] [Abstract][Full Text] [Related]
31. Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
Jia D; Taguchi M; Otsuki M
Pancreas; 2005 Jan; 30(1):54-61. PubMed ID: 15632700
[TBL] [Abstract][Full Text] [Related]
32. Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR-1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA.
Sazaki N; Miyasaka K; Matsumoto M; Funakoshi A
J Gastroenterol; 1995 Oct; 30(5):599-606. PubMed ID: 8574331
[TBL] [Abstract][Full Text] [Related]
33. Lack of trophic pancreatic effects in humans with long-term administration of ximelagatran.
Liddle RA; Toskes PP; Horrow J; Ghali J; Dachman A; Stong D
Pancreas; 2006 Mar; 32(2):205-10. PubMed ID: 16552342
[TBL] [Abstract][Full Text] [Related]
34. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors.
Povoski SP; Zhou W; Longnecker DS; Jensen RT; Mantey SA; Bell RH
Gastroenterology; 1994 Oct; 107(4):1135-46. PubMed ID: 7523219
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic polyamine concentrations and cholecystokinin plasma levels in rats after feeding raw or heat-inactivated soybean flour.
Löser C; Fölsch UR; Mustroph D; Cantor P; Wunderlich U; Creutzfeldt W
Pancreas; 1988; 3(3):285-91. PubMed ID: 3387422
[TBL] [Abstract][Full Text] [Related]
36. Endogenous CCK release and pancreatic growth in rats after feeding a proteinase inhibitor (camostate).
Göke B; Printz H; Koop I; Rausch U; Richter G; Arnold R; Adler G
Pancreas; 1986; 1(6):509-15. PubMed ID: 3562444
[TBL] [Abstract][Full Text] [Related]
37. Changes in gene expression of pancreatitis-associated protein and pancreatic secretory trypsin inhibitors in experimental pancreatitis produced by pancreatic duct occlusion in rats: comparison with gene expression of cholecystokinin and secretin.
Funakoshi A; Miyasaka K; Jimi A; Nakamura E; Teraoka H
Pancreas; 1995 Aug; 11(2):147-53. PubMed ID: 7479671
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic atrophy in rats produced by the cholecystokinin-A receptor antagonist devazepide.
Nylander AG; Chen D; Ihse I; Rehfeld JF; Håkanson R
Scand J Gastroenterol; 1992 Sep; 27(9):743-7. PubMed ID: 1411279
[TBL] [Abstract][Full Text] [Related]
39. Effects of daily fat or ethanol ingestion on the cholecystokinin- pancreas and the gastrin- enterochromaffin-like cell axes in rats.
Yamada H; Kimura K; Chen D
Digestion; 1998; 59(4):331-4. PubMed ID: 9693204
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferator Wyeth-14,643.
Obourn JD; Frame SR; Bell RH; Longnecker DS; Elliott GS; Cook JC
Toxicol Appl Pharmacol; 1997 Aug; 145(2):425-36. PubMed ID: 9266817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
